Board of directors

Gabriel Fitzgerald
Chairman of the board since 2021 Born: 1977MSc in Finance from the Stockholm School of Economics and University Medical studies at Linköping University.
Board member of Fidelio Capital AB, and a number of subsidiaries within the Fidelio Capital AB-group, and the Group. Chairman of the board of Berghamnen AB and board member of Pencey Holding AB and Bellbox Holding AB.
CEO of Fidelio Capital, Investment Manager at Nordic Capital and Associate at Carnegie Investment Bank.
Gabriel is an ultimate beneficial owner of Fidelio Vet Holding AB, the Principal Owner of the Company.
The Company and executive management: Yes
Major shareholders: No

Mikael Dolsten
Board member since 2021 Born: 1958PhD in tumor immunology and M.D. from the University of Lund and visiting professor at Lund University, Medical Faculty.
Board member of Karyopharm Therapeutics.
Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, President of Worldwide R&D at Pfizer, President and Head of R&D at Wyeth Pharmaceuticals, Executive Vice President and Head of Pharmaceutical Research at Boehringer Ingelheim, Global VP at AstraZeneca.
0 ordinary shares, 0 C shares.
Subscribed for a total of 31,354 warrants in the Company under Board LTI 2021.
The Company and executive management: Yes
Major shareholders: Yes

Petra Rumpf
Board member since 2022 Born: 1967Bachelor’s degree in Economics from Trier University and MBA from Clark University, USA.
Member of the Supervisory Board at SHL-Medical, Zug. Member of the Supervisory Board, Chair of the ESG Task Force and member of the Technology Committee at Straumann Group. Member of the Supervisory Board and Chair of the Digital Advisory Board at VZUG, Zug. Member of the Advisory Board at Lima Corporate.
Member of the Executive Management Board and Global Head Dental Service Organizations at Straumann Group. Member of the Executive Committee of Nobel Biocare. Several years of experience in life science companies, the high-tech sector and over ten years of experience as a board member in companies within the MedTech industry.
40,000 ordinary shares, 0 C shares.
The Company and executive management: Yes.
Major shareholders: Yes.

Frida Westerberg
Board member since 2021 Born: 1975MSc in Finance and Business Administration from Stockholm School of Economics and a CEMS Master in International Management from Bocconi University in Milan.
Board member of Ework Group AB, Billogram AB, Trollheim Studios AB and Grebretsew AB. Deputy board member of Namrega AB.
CEO of European ID Security, CEO of IP-Only, Deputy CEO and COO of SF Studios, EVP M&A and Corporate Development at Bonnier Group and Associate at Goldman Sachs.
6,500 ordinary shares, 0 C shares.
Subscribed for a total of 20,903 warrants in the Company under Board LTI 2021.
The Company and executive management: Yes
Major shareholders: Yes

Martin Erleman
Board member since 2021 Born: 1983MSc in Finance from the Stockholm School of Economics.
Chairman of the board of a number of subsidiaries within the Group and the Fidelio Capital AB-group, and SBC Intressenter BidCo AB and SBC Intressenter HoldCo AB. Board member of a number of subsidiaries within the Fidelio Capital AB-group, SBC Sveriges Bostadsrättscentrum AB, Southern Meadow AB, Greenfood MC AB, Greenfood AB and Acetaria Holding AB.
Partner at Fidelio Capital, Investment Manager at Nordic Capital and Analyst at Goldman Sachs.
0 ordinary shares, 0 C shares.
0 warrants.
The Company and executive management: Yes
Major shareholders: No

Theodor Bonnier
Board member since 2021 Born: 1989BSc in Finance and Marketing from the Stockholm School of Economics.
Board member of a number of subsidiaries within the Group and the Fidelio Capital AB-group, Bellbox Holding AB, TBON Invest AB, Chino BidCo ApS and Chino Holding ApS. Deputy board member of WF Simhold AB, a number of subsidiaries within the Fidelio Capital AB-group, Auxo AB and Bisslinge Finans AB.
Director at Fidelio Capital.
0 ordinary shares, 0 C shares.
0 warrants.
The Company and executive management: Yes
Major shareholders: No